Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy

Am J Hematol. 2020 Dec;95(12):E319-E321. doi: 10.1002/ajh.25967. Epub 2020 Sep 3.

Authors

Elisa Bossi^{1

2}, Andrea Aroldi^{1

2}, Filippo A Brioschi^{1

2}, Carolina Steidl^{1

2}, Silvia Baretta¹, Rossella Renso¹, Luisa Verga¹, Diletta Fontana², Geeta G Sharma², Luca Mologni², Lara Mussolin^{3

4}, Rocco Piazza^{1

2}, Carlo Gambacorti-Passerini^{1

2}

Affiliations

¹ Hematology Division, San Gerardo Hospital, Monza, Italy.
² Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
³ Department Women's and Children's Health, Clinic of Pediatric Hemato-Oncology, University of Padua, Padua, Italy.
⁴ Institute of Pediatric Research, Fondazione Città della Speranza, Padova, Italy.

PMID: 32808682
DOI: 10.1002/ajh.25967

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Anaplastic Lymphoma Kinase / antagonists & inhibitors*
Crizotinib / administration & dosage*
Disease-Free Survival
Drug Resistance, Neoplasm / drug effects*
Female
Humans
Lymphoma, Large-Cell, Anaplastic* / drug therapy
Lymphoma, Large-Cell, Anaplastic* / enzymology
Lymphoma, Large-Cell, Anaplastic* / mortality
Male
Middle Aged
Protein Kinase Inhibitors / administration & dosage*
Recurrence
Survival Rate

Substances

Protein Kinase Inhibitors
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase